ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

ClinicalTrials.gov ID: NCT00347412

Public ClinicalTrials.gov record NCT00347412. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Study identification

NCT ID
NCT00347412
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Enrollment
903 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • NOV-002 Drug
  • Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2006
Primary completion
Dec 31, 2009
Completion
Jan 31, 2010
Last update posted
Jul 24, 2022

2006 – 2010

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Northwest Alabama Cancer Center Muscle Shoals Alabama 35661
Sharp Memorial Hospital San Diego California 92123
University of Chicago Medical Center Chicago Illinois 60637
Northern Indiana Cancer Research Consortium South Bend Indiana 46601
St. Agnes Hospital Baltimore Maryland 21229
Massachusetts General Hospital Boston Massachusetts 02144
University of Minnesota Medical Center, Fairview Minneapolis Minnesota 55455
Park Nicollet Clinic - Cancer Center St. Louis Park Saint Louis Park Minnesota 55416
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Cleveland Clinic Foundation Taussig Cancer Center Cleveland Ohio 44195
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107
South Texas Institute of Cancer Corpus Christi Texas 78405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00347412, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 24, 2022 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00347412 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →